Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

[1]  R. Suzuki,et al.  Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation , 2016, Leukemia.

[2]  R. Varadhan,et al.  Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation , 2016, Leukemia.

[3]  G. Rosner,et al.  Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  Shannon R. McCurdy,et al.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Shannon R. McCurdy,et al.  Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. , 2015, Blood.

[6]  G. Ruiz-Argüelles,et al.  [Donor cell leukemia (DCL): A prospective study of its identification and treatment]. , 2015, Gaceta medica de Mexico.

[7]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[8]  G. Rosner,et al.  Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. , 2014, Blood.

[9]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[10]  Christopher G. Kanakry,et al.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Wagner,et al.  Donor‐derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response , 2014, British journal of haematology.

[12]  S. Jhanwar,et al.  Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells , 2014, Leukemia research reports.

[13]  B. Hales,et al.  Effects of Four Chemotherapeutic Agents, Bleomycin, Etoposide, Cisplatin, and Cyclophosphamide, on DNA Damage and Telomeres in a Mouse Spermatogonial Cell Line1 , 2014, Biology of reproduction.

[14]  C. Huff,et al.  Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Richard J. Jones,et al.  HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. , 2012, Blood.

[16]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[17]  D. Wiseman.  Donor cell leukemia: a review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  B. Yeap,et al.  Donor-derived second hematologic malignancies after cord blood transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Allen R. Chen,et al.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. , 2010, Blood.

[20]  C. Huff,et al.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  L. Luznik,et al.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation , 2010, Immunologic research.

[22]  Ashkan Emadi,et al.  Cyclophosphamide and cancer: golden anniversary , 2009, Nature Reviews Clinical Oncology.

[23]  T. Chou,et al.  Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma , 2009, International journal of hematology.

[24]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  T. Naoe,et al.  Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review , 2008, International journal of hematology.

[26]  I. Bernstein,et al.  Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Suissa,et al.  Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. , 2008, Archives of internal medicine.

[28]  B. V. D. Reijden,et al.  Therapy-related, donor-derived AML responding to a second allogeneic BMT , 2007, Bone Marrow Transplantation.

[29]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[30]  D. Kaufman,et al.  Donor cell leukemia: insight into cancer stem cells and the stem cell niche. , 2007, Blood.

[31]  J. Radich,et al.  Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Y. Tanizawa,et al.  Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation , 2006, Leukemia.

[33]  K. Foucar,et al.  Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T‐cell acute lymphoblastic leukemia: Case report and review of the literature , 2006, American journal of hematology.

[34]  J. Wagner,et al.  First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. , 2005, Blood.

[35]  Y. Niitsu,et al.  Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T‐cell lymphoma , 2005, American journal of hematology.

[36]  J. Bergh,et al.  Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Gratwohl,et al.  Transmission of donor illness by stem cell transplantation: should screening be different in older donors? , 2004, Bone Marrow Transplantation.

[38]  J. Bryant,et al.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Greaves,et al.  Chromosome translocations and covert leukemic clones are generated during normal fetal development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Nah,et al.  Telomere length changes in patients undergoing hematopoietic stem cell transplantation , 1999, Bone Marrow Transplantation.

[41]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[42]  T. Dexter,et al.  Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants , 1998, The Lancet.

[43]  A. Cimmino,et al.  In vivo telomere dynamics of human hematopoietic stem cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Kwoh,et al.  Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. , 1995, Arthritis and rheumatism.

[45]  R N Hoover,et al.  Risk of leukemia after chemotherapy and radiation treatment for breast cancer. , 1992, The New England journal of medicine.

[46]  F. Appelbaum,et al.  Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. , 1990, The New England journal of medicine.

[47]  N Keiding,et al.  Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. , 1985, Annals of internal medicine.

[48]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[49]  Elias T. Zambidis,et al.  Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  R. Larson.  Etiology and management of therapy-related myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[51]  N. Schmitz,et al.  Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). , 2005, Haematologica.

[52]  E. Thomas,et al.  The incidence of recurrence of leukemia in donor cells after allogeneic bone marrow transplantation. , 1982, Leukemia research.